US Patent

US11976068 — 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

Formulation · Assigned to Oncoceutics Inc · Expires 2036-03-01 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treatment using a specific compound and its analogs, as well as pharmaceutical compositions containing them, for conditions such as cancer.

USPTO Abstract

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

Drugs covered by this patent

Patent Metadata

Patent number
US11976068
Jurisdiction
US
Classification
Formulation
Expires
2036-03-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Oncoceutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.